Merck wins FDA nod for first oral PCSK9 pill

Good morning, healthcare professional.

The FDA has cleared a significant barrier in cardiovascular medicine with approval of the first oral PCSK9 inhibitor, while a major pharmaceutical player places a multibillion-dollar wager on psychedelics for mental health. Meanwhile, federal regulators are preparing to reshape how Medicare pays for artificial intelligence tools, and a controversial new platform now lets investors bet real money on drug trial outcomes.

These developments signal shifting dynamics across drug innovation, reimbursement policy, and the financial mechanisms surrounding pharmaceutical development. From novel delivery systems addressing patient adherence challenges to regulatory frameworks struggling to keep pace with AI adoption, today's stories highlight the industry's rapid evolution and the complex forces shaping its future.

In today's healthcare digest:

• FDA approves Merck's Lipfendra as first oral PCSK9 cholesterol medication
• Eli Lilly acquires AtaiBeckley for $2.8 billion to expand psychedelics portfolio
• CMS announces plans to revamp payment structure for clinical AI software
• Kalshi launches prediction markets for biopharma trial results and FDA decisions

Merck Secures First Oral PCSK9 Approval

The FDA has approved Merck's Lipfendra (enlicitide), making it the world's first oral PCSK9 inhibitor for lowering LDL cholesterol. The approval addresses a major limitation of existing PCSK9 drugs, which require injections and have faced adoption challenges despite their effectiveness.

Unpacked:

• Current PCSK9 inhibitors like Repatha and Praluent are injectable biologics that achieved only modest commercial success due to administration barriers.
• Lipfendra offers a convenient oral alternative for patients with cardiovascular disease or familial hypercholesterolemia who need additional LDL reduction.
• The approval positions Merck to capture significant market share in the multibillion-dollar cholesterol management space with improved patient adherence.

Lilly Bets Big on Psychedelics with $2.8B Deal

Eli Lilly will acquire AtaiBeckley for $2.8 billion, marking one of the largest investments by a major pharmaceutical company in the psychedelics sector. The deal centers on mebufotenin, an investigational compound for treatment-resistant depression.

Unpacked:

• The acquisition validates psychedelics as a legitimate pharmaceutical category after years of regulatory and stigma-related challenges.
• AtaiBeckley's lead asset targets depression patients who haven't responded to conventional antidepressants, representing a substantial unmet medical need.
• Lilly's move follows growing clinical evidence supporting psychedelic-assisted therapies and signals broader industry interest in novel mental health approaches.

Medicare Prepares AI Payment Overhaul

CMS has signaled plans to fundamentally revise how it reimburses clinical software and artificial intelligence tools used in patient care. The policy shift could reshape the economics of health technology adoption across hospitals and physician practices.

Unpacked:

• Current payment models weren't designed for AI-driven diagnostics and decision support, creating reimbursement uncertainty for healthcare providers.
• The proposed changes would establish clearer pathways for AI tool coverage while potentially linking payments to demonstrated clinical value.
• Health technology companies and providers have lobbied for payment reform as AI adoption accelerates without corresponding reimbursement frameworks.

Prediction Markets Come to Drug Development

Kalshi has launched prediction markets allowing people to place financial bets on clinical trial outcomes and FDA approval decisions. The platform introduces a new layer of speculation to pharmaceutical development, raising questions about market transparency and potential conflicts of interest.

Unpacked:

• Participants can now wager real money on whether specific drugs will succeed in trials or gain regulatory clearance.
• The offering creates novel dynamics around information asymmetry, insider trading concerns, and the financialization of medical research outcomes.
• Regulators may face pressure to address whether betting markets on drug approvals create inappropriate incentives or compromise trial integrity.

The Shortlist

• Celcuity gained FDA approval for Revtorpyk, a closely-watched treatment for specific breast cancer subtypes.

• Johnson & Johnson reported strong earnings despite patent losses, with Tremfya offsetting Stelara biosimilar competition.

• Novo Nordisk secured European Commission approval for oral Wegovy, gaining a head start over Lilly in the European weight-loss market.

• Veradermics reported positive results for oral minoxidil in treating female pattern hair loss, expanding the drug's potential applications.

• Glenmark agreed to pay $29.6 million to settle long-running price-fixing allegations with multiple states.